<html>
<head>PUBMED IDs for CYP4Z2P</head>
<body bgcolor='#C5F0F2'><h1>CYP4Z2P</h1><a href='https://pubmed.ncbi.nlm.nih.gov/15059886/'>Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma.</a> April 3  2004<br><a href='https://pubmed.ncbi.nlm.nih.gov/25281903/'>Pseudogene CYP4Z2P 3'UTR promotes angiogenesis in breast cancer.</a> July 15  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25701119/'>The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.</a> December 15  2015<br><a href='https://pubmed.ncbi.nlm.nih.gov/26227178/'>Recurrent fusion transcripts detected by whole-transcriptome sequencing of 120 primary breast cancer samples.</a> June 14  2015<br><a href='https://pubmed.ncbi.nlm.nih.gov/26980484/'>Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.</a> January 7  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/28236635/'>The competing endogenous RNA network of CYP4Z1 and pseudogene CYP4Z2P exerts an anti-apoptotic function in breast cancer.</a> February 26  2017<br><a href='https://pubmed.ncbi.nlm.nih.gov/28403188/'>Molecular pathways associated with blood pressure and hexadecanedioate levels.</a> April 22  2017<br></body></html>
